For those aiming to surpass market returns, the art of stock picking is crucial. Making wise choices in stocks can greatly enhance your overall wealth.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The closing price of Cytokinetics Inc (NASDAQ: CYTK) was $54.50 for the day, down -0.69% from the previous closing price of $54.88. In other words, the price has decreased by -$0.69 from its previous closing price. On the day, 0.95 million shares were traded. CYTK stock price reached its highest trading level at $54.7 during the session, while it also had its lowest trading level at $53.82.
Ratios:
Our analysis of CYTK’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 10.39 and its Current Ratio is at 10.39. In the meantime, Its Debt-to-Equity ratio is 7.28 whereas as Long-Term Debt/Eq ratio is at 7.00.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for the company, Goldman on August 13, 2024, Downgraded its rating to Neutral and sets its target price to $60 from $85 previously.
On January 24, 2024, UBS Downgraded its rating to Neutral which previously was Buy and also upped its target price recommendation from $61 to $92.
Morgan Stanley Downgraded its Overweight to Equal-Weight on January 05, 2024, whereas the target price for the stock was revised from $60 to $90.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Oct 09 ’24 when Blum Robert I sold 5,000 shares for $55.61 per share. The transaction valued at 278,050 led to the insider holds 397,456 shares of the business.
ROBERT BLUM bought 5,000 shares of CYTK for $278,062 on Oct 09 ’24. On Oct 01 ’24, another insider, Malik Fady Ibraham, who serves as the EVP Research & Development of the company, sold 7,300 shares for $52.10 each. As a result, the insider received 380,297 and left with 118,920 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, CYTK now has a Market Capitalization of 6457160192 and an Enterprise Value of 6145847808. For the stock, the TTM Price-to-Sale (P/S) ratio is 2048.71 while its Price-to-Book (P/B) ratio in mrq is 59.01. Its current Enterprise Value per Revenue stands at 1961.024 whereas that against EBITDA is -12.462.
Stock Price History:
Over the past 52 weeks, CYTK has reached a high of $110.25, while it has fallen to a 52-week low of $30.37. The 50-Day Moving Average of the stock is -0.80%, while the 200-Day Moving Average is calculated to be -14.84%.
Shares Statistics:
CYTK traded an average of 1.25M shares per day over the past three months and 1052600 shares per day over the past ten days. A total of 117.66M shares are outstanding, with a floating share count of 113.74M. Insiders hold about 3.33% of the company’s shares, while institutions hold 113.83% stake in the company. Shares short for CYTK as of 1727654400 were 17322576 with a Short Ratio of 13.88, compared to 1724976000 on 18207015. Therefore, it implies a Short% of Shares Outstanding of 17322576 and a Short% of Float of 22.5.
